FDA Approves Amarin ' s Vascepa for CV Risk Reduction FDA Approves Amarin ' s Vascepa for CV Risk Reduction

The purified, high-dose form of eicosapentaenoic acid was approved for elevated triglycerides as an add-on to high-dose statins, following a unanimously positive advisory-panel recommendation.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news